Lufotrelvir: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -22% 1 58 Improvement, Studies, Patients Relative Risk Mortality -22% 1 58 RCTs -22% 1 58 Late -22% 1 58 Lufotrelvir for COVID-19 c19early.org December 2025 Favorslufotrelvir Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Grandits (DB RCT) -22% 1.22 [0.50-2.98] death 9/32 6/26 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.68 Late treatment -22% 1.22 [0.50-2.98] 9/32 6/26 22% higher risk All studies -22% 1.22 [0.50-2.98] 9/32 6/26 22% higher risk 1 lufotrelvir COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.68 Effect extraction pre-specified(most serious outcome) Favors lufotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Grandits (DB RCT) -22% 1.22 [0.50-2.98] 9/32 6/26 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.68 Late treatment -22% 1.22 [0.50-2.98] 9/32 6/26 22% higher risk All studies -22% 1.22 [0.50-2.98] 9/32 6/26 22% higher risk 1 lufotrelvir COVID-19 mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.68 Favors lufotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Grandits (DB RCT) -22% 1.22 [0.50-2.98] death 9/32 6/26 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.68 Late treatment -22% 1.22 [0.50-2.98] 9/32 6/26 22% higher risk All studies -22% 1.22 [0.50-2.98] 9/32 6/26 22% higher risk 1 lufotrelvir COVID-19 serious outcome c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.68 Effect extraction pre-specified(most serious outcome) Favors lufotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Grandits (DB RCT) 44% 0.56 [0.29-1.10] no disch. 9/32 13/26 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.094 Late treatment 44% 0.56 [0.29-1.10] 9/32 13/26 44% lower risk All studies 44% 0.56 [0.29-1.10] 9/32 13/26 44% lower risk 1 lufotrelvir COVID-19 recovery result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.094 Favors lufotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Grandits (DB RCT) -22% 1.22 [0.50-2.98] death 9/32 6/26 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.68 Late treatment -22% 1.22 [0.50-2.98] 9/32 6/26 22% higher risk All studies -22% 1.22 [0.50-2.98] 9/32 6/26 22% higher risk 1 lufotrelvir COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.68 Effect extraction pre-specified(most serious outcome) Favors lufotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Grandits (DB RCT) -22% 1.22 [0.50-2.98] 9/32 6/26 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.68 Late treatment -22% 1.22 [0.50-2.98] 9/32 6/26 22% higher risk All studies -22% 1.22 [0.50-2.98] 9/32 6/26 22% higher risk 1 lufotrelvir COVID-19 RCT mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.68 Favors lufotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Grandits (DB RCT) -22% 1.22 [0.50-2.98] death 9/32 6/26 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.68 Late treatment -22% 1.22 [0.50-2.98] 9/32 6/26 22% higher risk All studies -22% 1.22 [0.50-2.98] 9/32 6/26 22% higher risk 1 lufotrelvir COVID-19 peer reviewed studies c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.68 Effect extraction pre-specified(most serious outcome) Favors lufotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Grandits (DB RCT) -22% 1.22 [0.50-2.98] death 9/32 6/26 Improvement, RR [CI] Treatment Control Grandits (DB RCT) 44% 0.56 [0.29-1.10] no disch. 9/32 13/26 Lufotrelvir COVID-19 outcomes c19early.org December 2025 Favors lufotrelvir Favors control